Piper Sandler analyst Kelsey Goodwin raised the firm’s price target on Erasca (ERAS) to $18 from $11 and keeps an Overweight rating on the shares. The firm notes the company reported Q4/ FY2025 earnings that most notably confirmed the first half of 2026 ERAS-0015 update will include both U.S. and China data. Piper continues to think Erasca has a potentially best-in-class pan-RAS inhibitor capable of showing differentiation vs daraxonrasib and addressing the substantial RAS-mutant cancer market.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ERAS:
- Erasca price target raised to $19 from $16 at Mizuho
- Erasca reports Q4 EPS (10c), consensus (11c)
- Erasca: Pan-RAS Data Momentum and Strategic Partnerships Underpin Upsized Revenue Outlook and Buy Rating
- Erasca price target raised to $20 from $10 at Stifel
- Erasca exercises option to secure worldwide rights for ERAS-0015